Pimecrolimus and tacrolimus, 2 topical calcineurin inhibitors for the treatment of atopic dermatitis (AD), were not shown to increase the risk of cancer based on moderate-certainty evidence from a ...
Please provide your email address to receive an email when new articles are posted on . LOUISVILLE, Ky. — Researchers showed with moderate certainty that topical calcineurin inhibitors did not ...
The panel examines the evolution of atopic dermatitis (AD) treatment beyond topical steroids and calcineurin inhibitors, while evaluating the safety and efficacy of a specific topical therapy in AD ...
A review published in JAAD discussed the off-label use of systemic tacrolimus and voclosporin in patients with various dermatologic conditions. Tacrolimus is approximately 100 times more potent than ...
Am J Health Syst Pharm. 2006;63(23):2340-2348. MDR1 (ABCB1) T-129C, C1236T, G2677(T,A), C3435T No difference observed for cyclosporine and any CYP3A5 polymorphism Wild-type carriers of MDR1 (ABCB1) ...
In a comprehensive pharmacovigilance analysis, topical calcineurin inhibitors (TCIs) were not associated with a statistically significant lymphoma safety signal in patients with atopic dermatitis when ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results